Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants: Virology

• Published in: Clinical microbiology and infection Vol. 22; no. 2; pp. 191 - 200
• Main Authors: Noguera-Julian, M, Cozzi-Lepri, A, Di Giallonardo, F, Schuurman, R, Daeumer, M, Aitken, S, Ceccherini-Silberstein, F, D'Arminio Monforte, A, Geretti, A M, Booth, CL, Kaiser, R, Michalik, C, Jansen, K, Masquelier, B, Bellecave, P, Kouyos, R D, Castro, E, Furrer, H, Schultze, A, Guenthard, H F, Brun-Vezinet, F, Metzner, K J, Paredes, R, Paredes, Roger, Metzner, Karin J, Cozzi-Lepri, Alessandro, Schuurman, Rob, Brun-Vezinet, Francoise, Guenthard, Huldrych, Ceccherini-Silberstein, Francesca, Kaiser, Rolf, Geretti, Anna Maria, Brockmeyer, Norbert, Masquelier, Bernard
• Format: Journal Article
• Language: English
• Published: 01.02.2016
• Subjects: Human immunodeficiency virus 1
• ISSN: 1198-743X
• DOI: 10.1016/j.cmi.2015.10.004

Plasma drug-resistant minority human immunodeficiency virus type 1 variants (DRMVs) increase the risk of virological failure to first-line non-nucleoside reverse transcriptase inhibitor antiretroviral therapy (ART). The origin of DRMVs in ART-naive patients, however, remains unclear. In a large pan-...